Elite in Cushing's syndrome due to Adrenal Tumor

Martin Fassnacht

Josef Schneider Str. 2, 
Wuerzburg, BY, DE 
Elite in Cushing's syndrome due to Adrenal Tumor
Josef Schneider Str. 2, 
Wuerzburg, BY, DE 
OverviewLocationsClinical Research

Overview

Martin Fassnacht practices in Wuerzburg, Germany. Mr. Fassnacht is rated as an Elite expert by MediFind in the treatment of Cushing's syndrome due to Adrenal Tumor. His top areas of expertise are Adrenocortical Carcinoma, Adrenal Cancer, Adrenal Gland Adenoma, Gastric Bypass, and Lymphadenectomy.

His clinical research consists of co-authoring 399 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Cushing's syndrome due to Adrenal Tumor.

Gender
Male

Locations

Josef Schneider Str. 2, Wuerzburg, BY 97080, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
Enrollment Status: Terminated
Publish Date: November 12, 2024
Intervention Type: Biological
Study Drugs: EO2041, Nivolumab
Study Phase: Phase 1/Phase 2
First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)
First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)
Enrollment Status: Completed
Publish Date: August 04, 2022
Intervention Type: Drug
Study Drug: Sunitinib
Study Phase: Phase 2
Phase 1 Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma
Phase 1 Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma
Enrollment Status: Completed
Publish Date: November 06, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 2 Less Clinical Trials

398 Total Publications

In-depth analysis of metabolic hormones and inflammatory markers following Roux-en-Y gastric bypass in humans and rodents: similarities and differences.
In-depth analysis of metabolic hormones and inflammatory markers following Roux-en-Y gastric bypass in humans and rodents: similarities and differences.
Journal: Diabetes research and clinical practice
Published: August 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Fassnacht's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 11 Advanced Conditions
View All 40 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile